Oficiálny časopis Slovenskej kardiologickej spoločnosti,
Slovenskej hypertenziologickej spoločnosti a Slovenskej asociácie srdcových arytmií

Cardiology Letters 2022, 31(5):329-333

Coronary artery aneurysm after Kawasaki disease

Fabo P1,2, Olejnik P1,2
1 Department of Paediatric Cardiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia and
2 Department of Paediatric Cardiology, Paediatric Cardiac Centre, National Institute of Cardiovascular Diseases of Slovak Republic, Bratislava, Slovakia

The complication of coronary artery aneurysm development after Kawasaki disease is currently not common after introducing human immunoglobulin therapy. Still, it is a life-threatening complication requiring consistent life-long follow-up to avoid acute coronary syndrome. We present a case report of a Kawasaki disease patient with initial large coronary artery aneurysm regressing to medium size coronary artery aneurysm. Based on the recent recommendation from the American Heart Association for Kawasaki disease management, an adequate thromboprophylaxis was set in this patient.

Kľúčové slová: Kawasaki disease; coronary artery aneurysm; thromboprophylaxis; long-term follow-up

Uverejnené: May 1, 2022  Zobraziť citáciu

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fabo P, Olejnik P. Coronary artery aneurysm after Kawasaki disease. Cardiology Letters. 2022;31(5-6):329-333.
Share...
Stiahnuť citáciu
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Zobraziť celý článok

    Referencie

    1. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Chihara I, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol. 2010;20:302. Prejsť k pôvodnému zdroju...
    2. Holman R, Belay E, Christensen K, Folkema A, Steiner C, Schonberger L. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010;29:483. Prejsť k pôvodnému zdroju...
    3. Bar-Meir M, Haklai Z, Dor M. Kawasaki disease in Israel. Pediatr Infect Dis J. 2011;30:589. Prejsť k pôvodnému zdroju...
    4. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Originally published 29 Mar 2017, Correction 29 Jul 2019. Circulation. 2019;140:e181-e184.
    5. Nakamura Y, Yanagawa H, Kato H, Harada K, Kawasaki T. Mortality among patients with history of Kawasaki disease: the third look. The Kawasaki Disease Follow-up Group. Acta Paediatr Jpn. 1998;40:419. Prejsť k pôvodnému zdroju...
    6. Son M, Gauvreau K, Ma L, Baker A, Sundel R, Fulton D, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124:1. Prejsť k pôvodnému zdroju...
    7. Newburg J, Takahashi M, Burns J, Beiser A, Chung K, Duffy C, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-347. Prejsť k pôvodnému zdroju...
    8. Newburger J, Takahashi M, Gerber M, Gewitz M, Tani L, Burns J, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. American Heart Association. Circulation. 2004;110:2747. Prejsť k pôvodnému zdroju...
    9. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2:1055. Prejsť k pôvodnému zdroju...
    10. Newburger J, Takahashi M, Burns J, Beiser A, Chung K, Duffy C, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341 Prejsť k pôvodnému zdroju...
    11. Hirohisa K, Tetsu S, Teiji A, Noboru S, Kanoko H, Yasuki M. Long-term consequences of Kawasaki disease. Circulation. 1996;94:1379-1385. Prejsť k pôvodnému zdroju...
    12. Tsuda E, Hashimoto S. Time course of coronary artery aneurysms in Kawasaki disease. J Pediatr. 2021 Mar; 230:133-139e2. Prejsť k pôvodnému zdroju...
    13. Abbassi V. Growth and normal puberty. Pediatrics. 1998;102(2 Pt 3):507. Prejsť k pôvodnému zdroju...
    14. Orenstein J, Shulman S, Fox L, Baker S, Takahashi M, Bhatti T, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One. 2012;7:e38998. Prejsť k pôvodnému zdroju...
    15. Manlhiot C, Brandão LR, Somji Z, Chesney AL, MacDonald C, Gurofsky RC, et al. Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities. Pediatr Cardiol 2010 Aug;31:834-842. Prejsť k pôvodnému zdroju...
    16. Suda K, Kudo Y, Higaki T, Nomura Y, Miura M, Matsumura M, et al. Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. Circ J. 2009 Jul;73:1319-1323. Prejsť k pôvodnému zdroju...
    17. Manlhiot C, Newburger JW, Low T, Dahdah N, Mackie AS, Raghuveer G. Low-molecular-weight heparin vs warfarin for thromboprophylaxis in children with coronary artery aneurysms after Kawasaki disease: A Pragmatic Registry Trial. Can J Cardiol. 2020 Oct;36:1598-1607. Prejsť k pôvodnému zdroju...

    Späť na obsah